Yabao Gains China Rights to Stroke Treatment from Primary Peptides

Yabao Pharma added another project to its development portfolio of innovative drugs by in-licensing greater China rights to a candidate for stroke treatment from Primary Peptides of Vancouver. Primary Peptides, which develops peptides that inhibit protein-protein interaction, says the K13 peptide was effective in animal models, even if administered as long as six hours after stroke onset. Yabao is busy on the deal-making front. One week ago, it announced a collaboration with the University of South Australia to develop new cancer drugs. More details.... Stock Symbol: (SHA: 600351) Share this with colleagues: // //